Safety Shot Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Safety Shot hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Ausschüttungsquote

Durchschnittlicher Branchenertrag	3.1%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Gewinn pro Aktie	-US$0.67
Prognose der Dividendenrendite	n/a

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

Jupiter Wellness inks exclusive licensing deal with Rejoy for new prescription products

Sep 20

Jupiter Wellness agrees with drug developer to refrain from exercising convertible note rights

Jul 26

Jupiter Wellness says developing a new women’s sexual health product

Jul 06

Jupiter Wellness: Advancing CBD-Based Medical Therapeutics And Wellness Products

Nov 30

Jupiter Wellness concludes enrollment in eczema study with JW-100

Dec 22

Vinco Ventures divests WOS to Jupiter Wellness

Dec 03

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von SHOT in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von SHOT gestiegen sind.

Dividendenrendite im Vergleich zum Markt

Safety Shot Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von SHOT im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (SHOT)	n/a
Untere 25 % des Marktes (US)	1.4%
Markt Top 25 % (US)	4.3%
Branchendurchschnitt (Personal Products)	3.1%
Analystenprognose (SHOT) (bis zu 3 Jahre)	n/a

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von SHOT im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von SHOT im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von SHOT, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da SHOT keine Ausschüttungen gemeldet hat.

Safety Shot Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

New major risk - Share price stability

Safety Shot, Inc. announced that it has received $3.421346 million in funding from Core 4 Capital Corp.

Safety Shot Clinical Data Results Confirm Breakthrough in Dramatic Reduction of Morning-After Symptoms Associated with Excessive Drinking

Health Check: How Prudently Does Safety Shot (NASDAQ:SHOT) Use Debt?

New major risk - Financial position

Safety Shot, Inc. to Release On-the-Go Powder Stick Packs of the First Alcohol Reducing Product

Safety Shot, Inc. announced that it expects to receive $1 million in funding

Safety Shot, Inc., Annual General Meeting, Jul 31, 2024

Safety Shot, Inc. Launch of Revolutionary Formula in New, Convenient 4-Ounce Bottles

First quarter 2024 earnings released: US$0.33 loss per share (vs US$0.051 loss in 1Q 2023)

Safety Shot, Inc. has filed a Follow-on Equity Offering in the amount of $4.999999 million.

New major risk - Revenue size

Full year 2023 earnings released: US$0.48 loss per share (vs US$0.70 loss in FY 2022)

Safety Shot, Inc. Appoints David J. Long to the Board of Directors

Safety Shot, Inc Appoints Jordan Schur as President and Company Board Member

Is Safety Shot (NASDAQ:SHOT) Using Debt In A Risky Way?

New minor risk - Market cap size

Safety Shot, Inc. Announces Chief Executive Officer Changes

Safety Shot, Inc. Appoints Danielle De Rosa as Chief Financial Officer, Effective March 1,2024

Less than half of directors are independent

Safety Shot Appoints Rich Pascucci to Its Board of Directors

Safety Shot, Inc. Announces West Coast Launch of Safety Shot

Safety Shot, Inc. announced delayed 10-Q filing

New major risk - Shareholder dilution

Safety Shot, Inc., Annual General Meeting, Dec 05, 2023

Safety Shot Inc. Announces Direct-To-Consumer Launch of Safety Shot

Safety Shot, Inc. Appoints Jarrett Boon to its Board of Directors

The Honorable Jack Brewer, M.Ed. Joins Safety Shot’s Advisory Board

Jupiter Wellness Appoints Jarrett Boon as COO

Jupiter Wellness Regains Compliance with Nasdaq Listing Rule 5550(a)(2)

Jupiter Wellness, Inc. Announces Chief Financial Officer Changes

Second quarter 2023 earnings released: US$0.013 loss per share (vs US$0.066 loss in 2Q 2022)

Jupiter Wellness, Inc. Appoints David Long to its Advisory Board

Jupiter Wellness, Inc Announces Board Appointments

Jupiter Wellness, Inc. Announces Executive Changes

New major risk - Share price stability

Jupiter Wellness, Inc. (NasdaqCM:JUPW) agreed to acquire Assets of GBB Drink Lab Inc.

First quarter 2023 earnings released: US$0.051 loss per share (vs US$0.13 loss in 1Q 2022)

Full year 2022 earnings released: US$0.69 loss per share (vs US$1.69 loss in FY 2021)

Jupiter Wellness, Inc. Appoints Hector Alila as Additional Director

Jupiter Wellness, Inc., Annual General Meeting, Dec 22, 2022

Jupiter Wellness Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jupiter Wellness Regains Compliance with Nasdaq Minimum Bid Price Requirement

Third quarter 2022 earnings released: US$0.11 loss per share (vs US$0.24 loss in 3Q 2021)

Less than half of directors are independent

Jupiter Wellness, Inc. Re-Opens Enrollment in Clinical Trial Comparison of JW-100 and EUCRISA for the Treatment of Eczema

Director recently bought US$105k worth of stock

Jupiter Wellness, Inc. Initiates Clinical Trial for Potential New Treatment for Tinnitus

Jupiter Wellness to get US patent for minoxidil use in hair loss disorder

Jupiter Wellness inks exclusive licensing deal with Rejoy for new prescription products

Jupiter Wellness, Inc. Announces Board Changes, Effective September 15, 2022

Second quarter 2022 earnings released: US$0.066 loss per share (vs US$0.36 loss in 2Q 2021)

Jupiter Wellness agrees with drug developer to refrain from exercising convertible note rights

Jupiter Wellness says developing a new women’s sexual health product

Jupiter Wellness Receives Non-Compliance Notice from Nasdaq Related to Listing Rule 5635(c)

Jupiter Wellness Receives Non-Compliance Letter from Nasdaq

Jupiter Wellness, Inc. Appoints Prof. Andy Goren, MD as Chief Medical Officer

Jupiter Wellness, Inc. (NasdaqCM:JUPW) acquired Assets from Applied Biology, Inc. on June 21, 2022.

First quarter 2022 earnings released: US$0.13 loss per share (vs US$0.20 loss in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: US$1.69 loss per share (vs US$0.86 loss in FY 2020)

Jupiter Wellness, Inc. Announces Resignation of Ryan Allison as Chief Operating Officer

Less than half of directors are independent

Jupiter Wellness, Inc. Announces Executive Changes

Jupiter Wellness Communicates Nasdaq About Issue of Inadvertent Non-Compliance with Nasdaq Listing Rule 5635(C)

Jupiter Wellness, Inc. (NasdaqCM:JUPW) announces an Equity Buyback for $5 million worth of its shares.

Jupiter Wellness, Inc. (NasdaqCM:JUPW) signed a definitive agreement to acquire Next Frontier Brands.

Jupiter Wellness: Advancing CBD-Based Medical Therapeutics And Wellness Products

Third quarter 2021 earnings released: US$0.24 loss per share (vs US$0.088 loss in 3Q 2020)

CEO & Executive Director recently bought US$73k worth of stock

Second quarter 2021 earnings released: US$0.36 loss per share (vs US$0.062 loss in 2Q 2020)

Jupiter Wellness, Inc. Announces Inititation of Head-to-Head Trial Comparing JW-100 and Eucrisa® for the Treatment of Mild-to-Moderate Eczema

Jupiter Wellness, Inc. announced delayed annual 10-K filing

Jupiter Wellness, Inc. Announces Results of Clinical Study to Investigate the Safety and Efficacy of JW-100 its Proprietary Lotion Formulation for the Treatment of Atopic Dermatitis

New 90-day high: US$6.97